Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA study shows how satellite 'light pollution' hinders space telescopes - 2Most loved Road Food: Which One Prevails upon You?
- 3Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- 4Merz: 80% of Syrians in Germany should return in three years
- 5No injuries after blast at pro-Israel centre in the Netherlands
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- 4 DSLR Cameras for Amateurs in 2024
- 6 Financial plan 3D Printers with the Best Worth
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Australians told to continue Easter travel plans despite fuel shortages
- With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
